Theravance Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	80.33	64.38	57.42	51.35	55.31	71.86
Revenue Growth (YoY)	27.12%	12.12%	11.84%	-7.17%	-23.03%	-2.12%
Cost of Revenue	39.51	37.64	40.62	63.39	193.66	260.95
Gross Profit	40.82	26.74	16.8	-12.05	-138.35	-189.1
Selling, General & Admin	73.63	69.17	70.1	67.07	99.3	108.53
Operating Expenses	73.63	69.17	70.45	67.07	99.3	108.53
Operating Income	-32.81	-42.44	-53.65	-79.12	-237.64	-297.63
Interest Expense	-2.52	-2.55	-2.35	-6.37	-8.55	-8.55
Interest & Investment Income	7.54	4.98	9.02	6.74	2.01	4.74
Currency Exchange Gain (Loss)	-0.1	-0.1	0.1	-0.9	-0.9	-0.3
Other Non Operating Income (Expenses)	75.14	-	-	-	-	-1.61
EBT Excluding Unusual Items	47.24	-40.1	-46.88	-79.65	-245.08	-303.34
Merger & Restructuring Charges	-	-	-2.39	-12.84	-20.14	-
Gain (Loss) on Sale of Assets	-	-	-	2.71	-	-
Asset Writedown	-	-4.51	-	-	-	-
Other Unusual Items	-	-	-	-3.03	-	-
Pretax Income	47.24	-44.61	-49.27	-92.82	-265.22	-303.34
Income Tax Expense	17.9	11.8	5.92	0.01	-0.15	-8.52
Earnings From Continuing Operations	29.34	-56.42	-55.19	-92.82	-265.07	-294.82
Earnings From Discontinued Operations	-	-	-	964.96	65.65	16.81
Net Income	29.34	-56.42	-55.19	872.13	-199.43	-278.02
Net Income to Common	29.34	-56.42	-55.19	872.13	-199.43	-278.02
Shares Outstanding (Basic)	50	49	55	74	69	62
Shares Outstanding (Diluted)	51	49	55	74	69	62
Shares Change (YoY)	3.49%	-11.67%	-24.85%	5.95%	11.41%	12.11%
EPS (Basic)	0.59	-1.15	-1.00	11.85	-2.87	-4.46
EPS (Diluted)	0.58	-1.15	-1.00	11.85	-2.87	-4.46
Free Cash Flow	243.48	-11.87	-29.49	-187.56	-211.26	-257.02
Free Cash Flow Per Share	4.82	-0.24	-0.53	-2.55	-3.04	-4.12
Gross Margin	50.82%	41.53%	29.26%	-23.46%	-250.12%	-263.16%
Operating Margin	-40.85%	-65.91%	-93.43%	-154.09%	-429.65%	-414.19%
Profit Margin	36.53%	-87.63%	-96.11%	1698.54%	-360.55%	-386.90%
Free Cash Flow Margin	303.11%	-18.43%	-51.35%	-365.29%	-381.96%	-357.68%
EBITDA	-31.16	-40.73	-51.65	-76.08	-232.83	-294
EBITDA Margin	-38.80%	-63.26%	-89.94%	-148.18%	-	-
D&A For EBITDA	1.65	1.71	2	3.04	4.81	3.63
EBIT	-32.81	-42.44	-53.65	-79.12	-237.64	-297.63
EBIT Margin	-40.85%	-65.91%	-93.43%	-154.09%	-	-
Revenue as Reported	80.33	64.38	57.42	51.35	55.31	71.86
Advertising Expenses	-	4.3	5.1	8	9.3	6.3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.